Bellicum Pharmaceuticals, Inc. - BLCM STOCK NEWS

Bellicum Pharmaceuticals (BLCM) reported its Q2 2022 financial results, highlighting continued patient enrollment in the BPX-601 and BPX-603 clinical trials. R&D expenses decreased to $5.1 million from $6.7 million year-over-year, while G&A expenses also saw a decline. The company recorded a net loss of $4.0 million, an increase from the previous year's loss of $2.2 million. Cash and cash equivalents stood at $34.7 million, down from $47.7 million at the end of 2021. Interim data updates for BPX-601 and BPX-603 are expected in early to mid-2023.

Bellicum Pharmaceuticals (NASDAQ:BLCM) announced equity inducement grants of 135,000 stock options to two new employees, effective June 30, 2022. The options have an exercise price of $1.18 per share, vesting over four years. 25% will vest on the one-year anniversary, with the remainder vesting monthly thereafter. This grant adheres to Nasdaq Listing Rule 5635(c)(4) and is part of the company's equity incentive plan. Bellicum focuses on controllable cellular immunotherapies for cancer, aiming to produce more effective CAR-T therapies.

Bellicum Pharmaceuticals (BLCM) reported its Q1 2022 financial results, highlighting ongoing momentum in patient recruitment for its BPX-601 and BPX-603 clinical trials following COVID-19 delays. R&D expenses decreased to $4.5 million from $6.5 million year-over-year, while general and administrative costs fell to $1.5 million from $2.0 million. The net loss narrowed to $7.6 million compared to $11.3 million in Q1 2021, driven by an increase in stock price impacting warrant liabilities. Cash and equivalents were reported at $41.3 million, down from $47.7 million at year-end.

Bellicum Pharmaceuticals (NASDAQ:BLCM) announced equity inducement grants totaling 33,000 stock options to three new employees, approved by the Board of Directors on April 30, 2022. The options have an exercise price of $1.56 per share and vest over four years, starting with 25% vesting on the first anniversary. This grant is in accordance with Nasdaq Listing Rule 5635(c)(4) and is intended to incentivize the new hires. Bellicum specializes in developing innovative cell therapies, aiming to enhance CAR-T cell effectiveness.

Bellicum Pharmaceuticals (BLCM) reported a confirmed partial response in one of the first three metastatic castration-resistant prostate cancer (mCRPC) patients treated with BPX-601 in a Phase 1/2 study. Positive safety profile observed for BPX-603 in HER2+ tumors. A $35 million private placement is expected to extend cash runway into Q2 2023, funding ongoing clinical trials. Financially, Q4 2021 revenues were $0.5 million, with a net loss of $9.7 million. The company's cash position stood at $47.7 million, expected to cover operations into Q2 2023.

Bellicum Pharmaceuticals (Nasdaq: BLCM) announced that Rick Fair, President and CEO, will present at the B. Riley Securities 2022 Virtual Oncology Conference on January 27, 2022, at 4 p.m. ET. A live webcast will be available on the company's website, with a replay accessible afterward. Bellicum specializes in controllable cellular immunotherapies for cancer, with innovative GoCAR-T^® candidates like BPX-601 and BPX-603 that aim to enhance CAR-T cell therapy efficacy.

Bellicum Pharmaceuticals (BLCM) announced it has regained compliance with Nasdaq's Listing Rule 5550(b)(1) after confirming stockholders' equity of at least $2.5 million. This follows a successful private placement of equity securities that raised approximately $35 million before expenses. The company is now in compliance with the continued listing requirements of The Nasdaq Capital Market, enabling its common stock to remain listed.

Bellicum Pharmaceuticals announces interim results from its ongoing Phase 1/2 GoCAR-T clinical trials. Key highlights include a confirmed partial response in one patient with metastatic castration-resistant prostate cancer (mCRPC) treated with BPX-601 and a favorable safety profile for BPX-603 in HER2+ solid tumors. To support clinical development, the company has secured $35 million through a private equity placement. This funding is expected to extend cash runway into mid-2023 and aid further trials for both BPX-601 and BPX-603.

Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM) announced a licensing agreement with The University of Texas MD Anderson Cancer Center for the use of its CaspaCIDe safety switch technology. For Q3 2021, Bellicum reported revenues of $5.0 million, significantly up from $0.0 million in Q3 2020. The company achieved a net income of $1.2 million for the quarter. However, it faces compliance challenges with Nasdaq, as it was notified it did not regain compliance with the Market Value Rule, and risks delisting if a hearing is not requested by November 9, 2021.